Omega Says Bank's Rug-Pull Led Cash-Strapped Co. To Ch. 11

By Emlyn Cameron · February 12, 2025, 9:04 PM EST

Biotechnology company Omega Therapeutics, which hit Chapter 11 this week with over $140 million of debt and a restructuring agreement, has said it became insolvent because a bank that gave it...

To view the full article, register now.

Bankruptcy Scorecard

Summary

Biotechnology company Omega Therapeutics hit Chapter 11 in Delaware, listing over $140 million of debt on its petition and having filed a form with the U.S. Securities and Exchange Commission saying it had entered a restructuring agreement with an affiliate of its controlling stockholder.

Case Number

1:25-bk-10211

Judge

Brendan L. Shannon

Venue

U.S. Bankruptcy Court for the Northern District of Alabama

Capital Structure

Total Liabilities:

Over $140.4 million in debt

View Full Scorecard

Documents